Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy

(2018) William L. Hwang et al.   JAMA Oncology

Modulation of cancer-specific immune responses by amino acid degrading enzymes

(2017) Elina Timosenko et al.   Immunotherapy

Statistical and integrative system-level analysis of DNA methylation data

(2017) Andrew E. Teschendorff et al.   NATURE REVIEWS GENETICS

Epigenetic plasticity and the hallmarks of cancer

(2017) William A. Flavahan et al.   SCIENCE

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

(2016) Fernanda G. Herrera et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dendritic cell-based immunotherapy

(2016) Rachel L Sabado et al.   CELL RESEARCH

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

(2016) Aaron Goodman et al.   Nature Reviews Clinical Oncology

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Expression of Sox2 in breast cancer cells promotes the recruitment of M2 macrophages to tumor microenvironment

(2015) Wenjun Mou et al.   CANCER LETTERS

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer

(2015) V. K. Anagnostou et al.   CLINICAL CANCER RESEARCH

Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment

(2015) Joanna M. Poczobutt et al.   JOURNAL OF IMMUNOLOGY

Differential DNA mismatch repair underlies mutation rate variation across the human genome

(2015) Fran Supek et al.   NATURE

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity

(2015) Carolina S Ilkow et al.   NATURE MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Pharmacological DNA demethylation: Implications for cancer immunotherapy

(2015) David Roulois et al.   OncoImmunology

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

(2014) John C Castle et al.   BMC GENOMICS

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1

(2014) Deepa Kolaseri Krishnadas et al.   TUMOR BIOLOGY

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

(2013) Rakesh K. Jain   JOURNAL OF CLINICAL ONCOLOGY

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

(2013) E H Estey   LEUKEMIA

DNA methylation and differentiation: silencing, upregulation and modulation of gene expression

(2013) Melanie Ehrlich et al.   Epigenomics

Molecular Dissection of Microsatellite Instable Colorectal Cancer

(2013) Eduardo Vilar et al.   Cancer Discovery

Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)

(2012) Siddhartha Ganguly et al.   ANNALS OF HEMATOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT

(2011) S N Singh et al.   BONE MARROW TRANSPLANTATION

Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo

(2011) Oscar Alcazar et al.   INTERNATIONAL JOURNAL OF CANCER

Stem Cell Niche, the Microenvironment and Immunological Crosstalk

(2010) Law Sujata et al.   Cellular & Molecular Immunology

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

(2008) Carlo Stresemann et al.   INTERNATIONAL JOURNAL OF CANCER